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Intravenous Nitroglycerin for Acute Myocardial Infarction

Steven Borzak, MD'

Intravenous nitroglycerin (IV TNG) has been increasingly used in the setting of acute myocardial
infarction. The seven randomized trials comparing IV TNG with placebo, and one trial comparing IV
isosorbide dinitrate with furosemide, were reviewed for evidence of beneficial clinical effects. IV
TNG in low dosage is safe in the setting of acute myocardial infarction and modestly effective in
relieving chest pain. Favorable hemodynamic effects are most pronounced in patients with congestive
heart failure. Limited evidence suggests that IV TNG, particularly when administered early, reduces
both infarct size and mortality when given prophylactically. (Henry Ford Hosp Med J1991:39:206-9)

N

itrates have been used in the treatment of heart disease for
more than 120 years (1). The recent development of intravenous nitroglycerin (IV TNG) (2) has found widespread application in treating acute ischemia syndromes and, in particular,
acute myocardial infarction (MI). Therapeutic goals have included alleviation of symptoms, reduction of preload and afterload, limitation of infarct size and preservation of left ventricular (LV) function, and prevention of mortality. A total of seven
randomized trials (3-9) have compared the effect of IV TNG
with that of placebo on these endpoints. One trial compared IV
isosorbide dinitrate (ISDN) with furosemide (10). These studies
are briefiy reviewed and guidelines for the use of IV TNG in the
treatment of acute MI are discussed.

Nitrates for Symptomatic Relief
Sublingual and oral forms of nitroglycerin are well established for symptomatic relief of chronic angina. The efficacy of
IV TNG in relieving chest pain during acute MI was examined
in several of the randomized trials. Lis et al (8) found that 22%
of patients receiving IV TNG required morphine for pain control
during the first 24 hours of hospitalization, while 54% of patients in the placebo group required morphine, a significant difference. This finding was confirmed in the study of Bussmann et
al (4), who found that 39% of 31 pafients in the IV TNG group
required morphine, compared to 66% of patients in the control
group, also a significant difference. The difference in morphine
administration appeared to be limited to the patients in whom IV
TNG was initiated within 8 hours of symptom onseL In contrast,
in the study of Jaffe et al (5), morphine requirements averaged
11.4 mg/patient in the IV TNG group and 12.2 mg/patient in
the control group, a difference which was not significant. Since
staff members caring for patients in these trials were either not
blinded to treatment or would be expected to discem treatment
assignment during dose titration, it is possible that bias may
have influenced the results. Two studies (2,6) have shown a decrease in ST segment elevation (measured by precordial map-
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ping) in response to IV TNG, suggesfing a decrease in myocardial ischemia, but neither study compared ST changes to degree
of symptomatic relief.

Preload and Afterload Reduction
Nitrates have long been recognized as preload-reducing agents
and, to a lesser extent, as afterload-reducing agents. Through an
action to increase venous capacitance, ventricular filling pressure falls, especially when elevated above normal. A reduction
in LV filling pressure may decrease LV volume, an effect which
decreases wall stress and thereby myocardial oxygen consumption. Decreased diastolic volume may also increase coronary
blood flow independent of coronary va.sodilatation (11). In 12
patients with LV failure complicating acute infarcfion, low
doses of IV TNG sufficient to lower mean arterial pressure by
only 7 mm Hg, or 7%, caused mean LV filling pressure (measured as the pulmonary-capillary wedge pressure) to fall from
22 to 12 mm Hg, a 43% reducfion. This reduction was associated with a minimal decrease in cardiac index and no change in
stroke work index (2). In pafients with normal LV filling pressures, such effects are discemible but not as pronounced.
The hemodynamic profile of IV nitrates was contrasted with
that of furosemide-induced diuresis in a study reported by Nelson et al (10). In this protocol, 30 patients with LV failure complicating acute infarction were randomized to receive either furosemide at a dose of 1 mg/kg IV or IV ISDN titrated to reduce
mean arterial pressure by 10 mm Hg. For similar reductions in
LV filling pressure, IV ISDN produced a fall in arterial pressure
and systemic vascular resistance with no change in cardiac index, whereas furosemide produced no change in arterial pres-
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Table 1
Effect of Intravenous Nitroglycerin on Infarct Size

Reference
Bussmann et al (4)
Jaffe et al (5)
Jugdutt et al (6)
Flaherty et al (7)
Liset al(8)

Number of
Patients
60
X5
22
104
310

infarct Size*
IV TNG
Control
44122
11,2 ± 1,4
30,1 ± 4,4
ND
41

57 ±32
14,9 ±2.1
51,4± 10
ND
55

P-Value

Time to
Treatment

<0,05
0,06
<0,05
NS
< 0,001

10,2 hrs
6,2 hrs
5,7 hrs
< 12,0 hrs
8,5 hrst

*Measured as creatine kinase release in gram-equivalents, normalized to surface area
(g Eq/M-) in reference 5.
tTime lo randomization.
IV TNG = intravenous nitroglycerin, ND = no data provided, NS = not significant.

sure, a rise in systemic vascular resistance, and a fall in cardiac
index. No untoward events were observed in either group, nor
were relative clinical benefits of one agent over the other apparent over the course of several hours of observation. Nonetheless,
IV nitrates offered the theoretical advantage of maintained cardiac output and lowered vascular resistance and, by implication,
improved tissue perfusion.

Infarct Size Limitation
In the seven trials mentioned previously, the effect of IV TNG
on infarct size was measured by the magnitude and pattem of
creatine kinase (CK) and CK-MB isoform release, ST segment
precordial mapping, or both. Studies in which CK data were
available are displayed in Table I . Of these five studies, infarct
size was lower in the treatment group in three studies (4,6,8), a
favorable trend was observed in one study (5), and no effect was
seen overall in the report by Flaherty et al (7). In the latter study,
however, analysis of subsets within the populafion showed a favorable treatment effect for the group treated within 10 hours. A
more pronounced effect in patients treated earlier was found in
the four studies which stratified results into early and late subgroups. These subgroup analyses taken together suggest that
early treatment may be more effective than late treatment, but
this issue has not been addressed in a study designed for such a
question. The finding of Jaffe et al (5), that IV TNG reduced infarct size only for inferior infarctions, has not been duplicated
by other investigations.
A smaller infarct size as a result of IV TNG therapy may
translate into preserved ventricular function. Only two of the IV
TNG trials examined LV function prior to discharge as a clinical
endpoint. Flaherty et al (7) found no effect of IV TNG overall or
in the subset of patients given IV TNG within 10 hours from
symptom onset. Only when patients receiving early IV TNG
treatment were further divided into those with initially normal
(> 50%) or impaired (< 50%) ejection fractions was an effect
discovered: the former group had no change while the latter
group had an 11 % increase in ejection fraction from the initial to
predischarge study.
This issue was more powerfully addressed by Jugdutt and
Wamica (9) in a study of 310 patients prospectively designed to
measure LV regional and global function as an endpoint. Treat-
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Table 2
ElTect of Intravenous Nitroglycerin on
Left Ventricular Function and Volume*

LVEF(%)
LV asynergy (%)
LV end diastolic volume

Control (n = 67)
Baseline
10 Days

IV TNG (n = 61)
Baseline
10 Days

34 ± 8
27 ± 8
103 ± 3

37± 10
28 ± 8
108 ± 3

42 + 9
24±9
138 ± 5

51 ± 9 t
16±8t
I12±5t

*Data from Jugdutt and Wamica (9),
tSignifieantly different from control al 10 days,
IV TNG = intravenous nitroglycerin, LVEF = left ventricular ejection fracdon, LV = lefl
ventricular.

ment was begun an average of 8.1 hours after symptom onset in
the placebo group and 9.0 hours in the treatment group, with
about one-fifth of pafients receiving therapy within 4 hours. IV
TNG was titrated in order to lower mean arterial pressure by
10% (30% if initial pressure was greater than 140/90 mm Hg).
Echocardiography was performed before treatment and then serially unfil discharge, with overall LV function measured as
ejecfion fracfion and regional wall mofion defined by extent of
asynergy, by endocardial segment length in the infarct zone, and
by a derived expansion index and thinning ratio.
Some of the results from this study are shown in Table 2. All
three primary measurements of LV function and volume were favorably infiuenced by IV TNG. In addifion, IV TNG was found
to reduce the expansion index and thinning ratio when treated
patients were compared to controls. These important findings
point toward the potential role of IV TNG to modulate ischemic
damage and may explain the reducfion in mortality seen in this
trial and in pooled results from the smaller trials.
All of the clinical trials were conducted without IV thrombolytic therapy administration, which can also salvage myocardium. IV TNG has been found by several investigators to inhibit
platelet aggregation (12,13). However, one group found that IV
TNG diminished thrombolytic effectiveness oftissueplasminogen activator in a dog model of coronary thrombosis (14). IV
TNG has been found by some (15,16) but not all (17,18) investigators to antagonize the anticoagulant effect of heparin. Careful monitoring of the partial thromboplastin time was recommended, particularly when changes were made in IV TNG infusion rates. Whether IV TNG demonstrates synergy or interference, or whether its additive effect is only marginal when administered together with thrombolytic and anticoagulant agents,
is an important question not fully addressed by a clinical trial.

Mortality Reduction
The effect of IV TNG on mortality was examined by Yusuf et
al (19) using meta-analysis. This technique allows for the stmctured pooling of results from several smaller trials of similar but
not identical study design to arrive at a combined result. All but
two trials (4,9) showed a trend in favor of active treatment but
lacked sufficient power to demonstrate a statistically significant
result. When the results were combined, however, mortality was
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20.5% in control patients and 12% in treated patients, a 41% reduction corresponding to a typical odds ratio of 0.65 (P < 0.0001
with 95% confidence intervals of 0.51 to 0.82). Pooled results
from studies that provided long-term follow-up suggested that
the early in-hospital benefit was not rapidly lost.

Complications of IV TNG Therapy
The most predictable complication of IV TNG is dose-related
hypotension. In the studies of Jaffe et al (5) and Lis et al (8), an
excess of IV TNG patients became hypotensive compared to
the placebo group. On occasion, hypotension is associated with
bradycardia, a syndrome possibly mediated by vagal discharge
and generally responsive to volume expansion, atropine, and decrease or interruption of the IV TNG infusion (20). This situation may particularly be encountered in inferior infarction. Reflex tachycardia is encountered rarely when IV TNG is titrated
to a modest decrease in blood pressure; resting tachycardia is
not a contraindication to IV TNG use. IV TNG should be used
with caution in patients with right ventricular infarction, whose
cardiac output is dependent on high right-sided pressures due to
impaired right ventricular performance. In addition, volume-depleted patients may be sensitive to low doses of IV TNG and
also prone to hypotension. Volume depletion can occur because
of decreased oral intake and vomiting associated with the acute
infarction. IV TNG is particularly useful in hypertensive patients, though may not suffice as a single agent to adequately
lower blood pressure.
Tolerance to the effects of nitrates has been reported with increasing frequency (21). Tolerance is an important issue when
chronic oral nitrates or sustained IV TNG infusions are used for
unstable angina; when the goal is a 10% reduction in arterial
pressure for 48 hours, tolerance is less often encountered. Jugdutt and Wamica (22) reported that of the 154 patients who received IV TNG, 24% required an increase in dose to maintain
the reduction in blood pressure achieved by the initial titration.
The headache commonly encountered often responds to analgesia or dose reduction. Intoxication has been reported to result
from the ethanol solvent ofthe TNG preparation, but only with
doses of 2,000 pg/min or more (23).
The IV formulation is generally preferred to oral, topical, and
sublingual nitrate preparations because of the ease of dose titration in the early and acute stages of infarction. After 48 hours, in
stable patients, the IV infusion can be readily changed to chronic
intermittent oral or topical administration.

Conclusions and Recommendations
Review of the seven randomized trials of IV TNG shows that
this therapy is safe and well tolerated in the majority of patients
with acute MI. While relief of chest pain can sometimes be
achieved, IV TNG is no substitute for morphine or other analgesia. Favorable hemodynamic effects are seen in patients with
symptoms of congestive heart failure or elevated LV filling
pressures. IV TNG has the potential to limit infarct size and salvage myocardium; this may be one mechanism of the reduction
in mortality demonstrated with treatment, especially when initiated early in the course of infarction. Effects of IV TNG have
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Table 3
Guidelines for Use of Intravenous Nitroglycerin
in Acute Myocardial Infarction
Indications
As a primary therapy in patients with congestive heart failure or
recurrent ischemia
Relief of symptoms within acceptable blood pressure range and in
conjunction with analgesia
Prophylactic treatment of uncomplicated infarction for 48 hours
(controversial)
Therapeutic Goals
Reduction in mean arterial pressure:
By 10% in normotensive patients
By up to 30% in hypertensive patients
Maintaining mean arterial pressure > 80 mm Hg
Relief of symptoms within acceptable blood pressure ranges
Precautions/Contraindications
Cardiogenic shock
Right ventricular infarction
Initial agent for significant hypertension (blood pressure > 180/110 mm Hg)

not been extensively evaluated in patients who have received
thrombolytic therapy; it is possible that such patients may experience only marginal benefit when therapies are combined.
IV TNG should be considered a first-line agent—in addition
to other, standard measures—in patients with acute infarction
who have evidence of congestive heart failure or recurrent
ischemia. In patients with uncomplicated infarction, IV TNG is
most beneficial when started within 6 hours of the onset of
symptoms. Its prophylactic use in all pafients with uncomplicated infarction remains controversial. Despite the evidence reviewed, guidelines recently published by the Joint Task Force of
the American College of Cardiology and American Heart Association did not recommend the prophylactic use of IV TNG in
the absence of the specific indications discussed (24) (Table 3).
Ongoing investigation should clarify the clinical settings in
which IV TNG is most beneficial.
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